Plans are also underway to begin three additional Phase Ib expansion studies focusing on different combinations and patient ...

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program ...

Safety data from the new study will be closely watched, as Enhertu has been linked to some potentially serious side effects, including interstitial lung disease (ILD), although, the taxane ...

First-line treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) plus Perjeta (pertuzumab) demonstrated highly statistically significant and clinically meaningful improvement in progression-free ...

who have been previously treated with androgen receptor inhibitors and taxane-based chemotherapy or not medically suitable for taxane drugs. The approval – which applies to England, Scotland and ...

The first Phase 1b expansion study will enroll taxane-naïve mCRPC patients and is designed to generate additional safety and efficacy data in this first and second line (1L/2L) patient population.